Sigma 1 agonisti olan fluvoksaminin sıçanlarda tardif diskinezi belirtileri üzerine etkilerinin incelenmesi
Küçük Resim Yok
Tarih
2023
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Tekirdağ Namık Kemal Üniversitesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Tardif diskinezi uzun su?ren antipsikotik tedavisi ile ortaya c?ıkan, sıklıkla semptomları tedavi ile go?lgelenen ancak tedavi azaltıldıktan ya da sona erdirildikten sonra ac?ık bir şekilde ortaya c?ıkan istemsiz kompleks hareketlerdir. Bu araştırmanın amacı haloperidolu?n sıc?anlara kronik olarak uygulanması ile sıc?anlarda tardif diskinezi modeli oluşturmak; fluvoksamin tedavisi uygulanan sıc?an grubunu biyokimyasal ve davranışsal parametreler ac?ısından kontrol grubu, haloperidol grubu ve haloperidol+tetrabenazin grubu ile karşılaştırarak fluvoksaminin alternatif bir tedavi olup olmayacağını sınamaktır. Bu amac?la 32 adet Wistar Albino erkek rat kontrol grubu, haloperidol grubu, haloperidol+fluvoksamin grubu ve haloperidol+tetrabenazin grubu olmak u?zere 4 gruba ayrılmıştır. Ratların davranışsal go?zlemleri ac?ık alan testi ve yu?kseltilmiş artı labirent testi aracılığıyla gerc?ekleştirilmiş; ardından ratlardan hipokampus, striatum bo?lgesi ve frontal lob dokularından o?rnekler alınıp BDNF, NGF, SOD ve MDA du?zeyleri o?lc?u?lmu?ştu?r. Yapılan istatistik analizleri sonucunda davranış go?zlemleri ac?ısından gruplar arasında anlamlı farklar belirlenmiştir. Ayrıca haloperidol+fluvoksamin grubunun hipokampuste SOD; striatumda BDNF, NGF ve SOD du?zeyleri haloperidol grubuna go?re anlamlı du?zeyde yu?ksek bulunurken hipokampuste MDA du?zeyi haloperidol grubuna go?re anlamlı du?zeyde du?şu?k bulunmuştur. Ayrıca biyokimyasal parametreler ac?ısından haloperidol+tetrabenazin grubu ile diğer gruplar arasında da anlamlı farklar olduğu belirlenmiştir. Sonuc?ların, fluvoksaminin sigma 1 agonizması aracılığı ile beyin bu?yu?me fakto?rleri ve oksidatif stres fakto?rleri u?zerinde olumlu biyokimyasal değişiklikler ortaya c?ıkarak tardif diskinezinin tedavisi ve kompleks biyolojik mekanizmasının anlaşılmasına katkı sağlayacağı du?şu?nu?lmektedir. Anahtar kelimeler: Tardif diskinezi, fluvoksamin, beyin tu?revli no?rotrofik fakto?r (BDNF), sinir bu?yu?me fakto?ru? (NGF), superoksit dismutaz (SOD), malondialdehit (MDA) Anahtar kelimeler: Tardif diskinezi, fluvoksamin, beyin türevli nörotrofik faktör (BDNF), sinir büyüme faktörü (NGF), superoksit dismutaz (SOD), malondialdehit (MDA)
Tardive dyskinesia is involuntary complex movements that occur with long-term antipsychotic treatment, often whose symptoms are overshadowed by treatment, but become clear after treatment is reduced or terminated. The aim of this study was to establish a tardive dyskinesia model in rats by chronic administration of haloperidol to rats; to test whether fluvoxamine can be an alternative treatment by comparing the fluvoxamine treated rat group with the control group, haloperidol group and haloperidol+tetrabenazine group in terms of biochemical and behavioral parameters. For this purpose, 32 Wistar Albino male rats were divided into 4 groups as control group, haloperidol group, haloperidol+fluvoxamine group and haloperidol+tetrabenazine group. Behavioral observations of the rats were carried out by open field test and elevated maze test, then samples were taken from the hippocampus, striatum region and frontal lobe tissues and BDNF, NGF, SOD and MDA levels were measured. Significant differences were determined between the groups in terms of behavioral observations. SOD level in the hippocampus; BDNF, NGF and SOD levels in the striatum of the haloperidol+fluvoxamine group were found to be significantly higher than in the haloperidol group, while MDA levels in the hippocampus were found to be significantly lower than in the haloperidol group. In addition, it was determined that there were significant differences between the haloperidol+tetrabenazine group and the other groups in terms of biochemical parameters. It is thought that the results will contribute to the understanding of the complex biological mechanism and the treatment of tardive dyskinesia by revealing positive biochemical changes on brain growth factors and oxidative stress factors through the sigma 1 agonism of fluvoxamine. Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA) Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA)
Tardive dyskinesia is involuntary complex movements that occur with long-term antipsychotic treatment, often whose symptoms are overshadowed by treatment, but become clear after treatment is reduced or terminated. The aim of this study was to establish a tardive dyskinesia model in rats by chronic administration of haloperidol to rats; to test whether fluvoxamine can be an alternative treatment by comparing the fluvoxamine treated rat group with the control group, haloperidol group and haloperidol+tetrabenazine group in terms of biochemical and behavioral parameters. For this purpose, 32 Wistar Albino male rats were divided into 4 groups as control group, haloperidol group, haloperidol+fluvoxamine group and haloperidol+tetrabenazine group. Behavioral observations of the rats were carried out by open field test and elevated maze test, then samples were taken from the hippocampus, striatum region and frontal lobe tissues and BDNF, NGF, SOD and MDA levels were measured. Significant differences were determined between the groups in terms of behavioral observations. SOD level in the hippocampus; BDNF, NGF and SOD levels in the striatum of the haloperidol+fluvoxamine group were found to be significantly higher than in the haloperidol group, while MDA levels in the hippocampus were found to be significantly lower than in the haloperidol group. In addition, it was determined that there were significant differences between the haloperidol+tetrabenazine group and the other groups in terms of biochemical parameters. It is thought that the results will contribute to the understanding of the complex biological mechanism and the treatment of tardive dyskinesia by revealing positive biochemical changes on brain growth factors and oxidative stress factors through the sigma 1 agonism of fluvoxamine. Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA) Keywords: Tardive dyskinesia, fluvoxamine, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), malondialdehyde (MDA)
Açıklama
Sağlık Bilimleri Enstitüsü, Sağlık Bilimleri Ana Bilim Dalı, Nörobilim Bilim Dalı
Anahtar Kelimeler
Psikiyatri, Psychiatry
